Gartner L M, Lee K S, Vaisman S, Lane D, Zarafu I
J Pediatr. 1977 Apr;90(4):513-31. doi: 10.1016/s0022-3476(77)80360-0.
Hepatic transport and metabolism of bilirubin have been examined in term, premature, and postmature newborn Macaca mulatta (rhesus) monkeys with and without prior phenobarbital treatment of pregnant mother and neonate. In untreated neonates a biphasic pattern of physiologic unconjugated hyperbilirubinemia has been observed. Phase I was characterized by a rapid increase in serum bilirubin concentration to 4.5 mg/dl by 19 hours and an equally rapid decline to 1.0 mg/dl by 48 hours of age. Phase II was characterized by a stable elevation at 1.0 mg/dl (four times greater than in the adult) from 48 to 96 hourse of age, followed by a decline to normal adult concentrations thereafter. An identical pattern was observed in 29 normal, term human neonates, but the duration of each phase was approximately three times as long as that in the monkey. Phase I hyperbilirubinemia appears to result from a sixfold increase in bilirubin load presented to the liver in the neonatal period, combined with marked deficieny in hepatic bilirubin conjugation, the rate-limiting step during Phase I. Hepatic uptake of bilirubin is not rate limiting during Phase I but may contribute to Phase II hyperbilirubinemia. An increased bilirubin load persists throughout the first 19 days of life in the monkey. Phase I physiologic jaundice in the monkey neonate was completely eliminated by prenatal maternal and neonatal administration of phenobarbital. A threefold enhancement of hepatic conjugation of bilirubin (glucuronyl transferase activity) during Phase I entirely accounted for the prevention of hyperbilirubinemia. The bilirubin load was unaffected by administration of phenobarbital. Whereas in control neonates the bilirubin load slightly exceeded hepatic bilirubin conjugating capacity and resulted in retention of bilirubin, in phenobarbital-treated neonates, hepatic conjugating capacity slightly exceeded that required for the bilirubin load. Administration of phenobarbital failed to alter Phase II hyperbilirubinemia and did not enhance either maximal hepatic uptake or excretion of bilirubin. Hepatic glucuronly transferase activity was increased threefold during Phase II and during the remainder of the neonatal period. Premature birth retarded maturation of hepatic glucuronyl transferase activity. In one phenobarbital-treated premature monkey neonate, there was no apparent response to treatment. Accelerated maturation of bilirubin uptake, conjugation, and excretion of bilirubin was observed in one postmature monkey neonate.
我们研究了足月、早产和过期产的新生恒河猴(猕猴)肝脏对胆红素的转运和代谢情况,这些新生猴的母亲和自身在产前或产后是否接受过苯巴比妥治疗。在未经治疗的新生儿中,观察到生理性未结合型高胆红素血症呈双相模式。第一阶段的特征是血清胆红素浓度在出生后19小时迅速升至4.5mg/dl,并在48小时时同样迅速降至1.0mg/dl。第二阶段的特征是在出生后48至96小时内稳定维持在1.0mg/dl(比成年猴高四倍),之后降至正常成年浓度。在29名正常足月人类新生儿中观察到了相同的模式,但每个阶段的持续时间约为猴的三倍。第一阶段的高胆红素血症似乎是由于新生儿期肝脏所承受的胆红素负荷增加了六倍,同时肝脏胆红素结合能力明显不足,而这是第一阶段的限速步骤。在第一阶段,肝脏对胆红素的摄取不是限速步骤,但可能导致第二阶段的高胆红素血症。在猴的整个出生后19天内,胆红素负荷持续增加。猴新生儿第一阶段的生理性黄疸通过产前给母体和产后给新生儿使用苯巴比妥完全消除。第一阶段肝脏胆红素结合(葡萄糖醛酸转移酶活性)增强了三倍,这完全解释了高胆红素血症得到预防的原因。苯巴比妥的使用并未影响胆红素负荷。在对照新生儿中,胆红素负荷略超过肝脏胆红素结合能力,导致胆红素潴留;而在接受苯巴比妥治疗的新生儿中,肝脏结合能力略超过胆红素负荷所需水平。苯巴比妥的使用未能改变第二阶段的高胆红素血症,也未增强肝脏对胆红素的最大摄取或排泄。在第二阶段及新生儿期的其余时间,肝脏葡萄糖醛酸转移酶活性增加了三倍。早产延缓了肝脏葡萄糖醛酸转移酶活性的成熟。在一只接受苯巴比妥治疗的早产猴新生儿中,未观察到明显的治疗反应。在一只过期产猴新生儿中,观察到胆红素摄取、结合和排泄的成熟加速。